Evidence map›Paper›PMID 32669493›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer.

Masakatsu Nakamura, Toshimi Otsuka, Ranji Hayashi, Tomoe Horita, Masafumi Ota, Naoko Sakurai, Hikaru Takano, Tasuku Hayashi, Motona Kumagai, Sohsuke Yamada and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story.International journal of molecular sciences · 2021
    Review
  5. First line Immunotherapy for Non-Small Cell Lung Cancer.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Masakatsu NakamuraDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Toshimi OtsukaDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Ranji HayashiDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Tomoe HoritaDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Masafumi OtaDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Naoko SakuraiDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Hikaru TakanoDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Tasuku HayashiDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Motona KumagaiDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan.
Sohsuke YamadaDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan.
Tomiyasu ArisawaDepartment of Gastroenterology, Kanazawa Medical University, Japan.
Kanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg/m

Indexed as

Chemical and Drug Induced Liver InjuryAgedAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungFemaleHepatitisHumansJapanLung NeoplasmsMalePaclitaxelAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCarboplatinPaclitaxeldurvalumabimmune-related hepatitisnon-small cell lung cancer

Identifiers

PMID32669493
PMCPMC7691038
OpenAlexW3043457053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.